Beximco Pharma trading suspended on London bourse

Beximco Pharmaceuticals has announced that trading of its global depositary receipts (GDRs) on London's Alternative Investment Market (AIM) will be suspended from January 2, 2026, due to delays in publishing its annual financial results for the year ended June 30, 2025.

A GDR is a financial instrument issued by a depositary bank that represents shares in a foreign company. GDRs enable international companies to access investors worldwide by listing on local stock exchanges outside their home markets.

In a disclosure on December 19, the Bangladesh-based drug maker said it would be unable to publish its final results and annual report by December 31, 2025, the deadline stipulated under AIM Rule 19.

The company attributed the delay to its inability to hold a board meeting required to approve the accounts, owing to an ongoing legal dispute in the High Court over the Bangladesh Securities and Exchange Commission's move to appoint nine additional independent non-executive directors to Beximco's board.

Following the fall of the Sheikh Hasina-led government in August 2025, the BSEC proposed the appointment of the independent directors, a decision that Beximco challenged in court.

The drug maker said it would not be able to publish its final results and annual report by December 31, 2025, the deadline stipulated under AIM Rule 19

According to the company, the High Court is currently in recess, and the case will need to be reheard from the beginning before a newly constituted bench following a restructuring of High Court benches in 2025. As a result, a ruling is not expected before January 2026 at the earliest.

Despite the suspension of GDR trading on AIM, Beximco said its shares would continue to trade normally on the Dhaka Stock Exchange and the Chittagong Stock Exchange.

The company added that it would continue to make all necessary disclosures in line with AIM rules during the period of suspension.

Beximco Pharmaceuticals declared a 40 percent cash dividend for the year ended June 30, 2026. In the first two quarters of fiscal year 2024-25, the company reported earnings per share of Tk 7.87.

Each GDR of Beximco Pharmaceuticals last traded at £42.50 on December 24, 2025. The company's GDRs were originally issued on September 19, 2006.